Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch
Pharmacogenetics Working Group provide therapeutic recommendations for well‐known …

Part I of this article discussed the potential functional importance of genetic mutations and
alleles of the human cytochrome P450 2D6 (CYP2D6) gene. The impact of CYP2D6 …

The goals of the Association for Molecular Pathology Clinical Practice Committee's
Pharmacogenomics (PGx) Working Group are to define the key attributes of …

Pharmacogenetics is the study of how interindividual variations in the DNA sequence of
specific genes affect drug response. This article highlights current pharmacogenetic …

Inferring CYP2D6 phenotype from genotype is increasingly challenging, considering the
growing number of alleles and their range of activity. This complexity poses a challenge in …

Abstract Cytochrome P450 2D6 (CYP2D6) plays an important role in the metabolism and
bioactivation of about 25% of clinically used drugs including many antidepressants …

CYP2D6 has received intense attention since the beginning of the pharmacogenetic era in
the 1970s. This is because of its involvement in the metabolism of more than 25% of the …

Drug lag, recently discussed extensively in Japan, can be divided into two phases: clinical
development time and application review time. The former factor is still an important problem …

Introduction: The frequency of CYP2D6 alleles, related to either a lack of or increased
enzymatic activity, which may lead to poor metabolism (PM) or ultrarapid metabolism (UM) …

Pharmacogenetics has arrived in clinical psychiatric practice with the FDA approval of the
AmpliChip CYP450 Test that genotypes for two cytochrome P450 2D6 (CYP2D6) and 2C19 …